Allay Therapeutics scores $60m Series C
Allay Therapeutics, a clinical-stage biotechnology company, has raised $60 million in Series C financing.
Allay Therapeutics, a clinical-stage biotechnology company, has raised $60 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination